Impact of amyloid-PET in daily clinical management of patients with cognitive impairment fulfilling appropriate use criteria : Medicine

Journal Logo

Research Article: Observational Study

Impact of amyloid-PET in daily clinical management of patients with cognitive impairment fulfilling appropriate use criteria

Triviño-Ibáñez, Eva María MD, PhDa,b; Sánchez-Vañó, Raquel MDc,∗; Sopena-Novales, Pablo MD, PhDd; Romero-Fábrega, Juan Carlos MDe; Rodríguez-Fernández, Antonio MD, PhDa,b; Carnero Pardo, Cristóbal MD, PhDb,f; Martínez Lozano, María Dolores MDg; Gómez-Río, Manuel MD, PhDa,b

Editor(s): Tusconi., Massimo

Author Information
doi: 10.1097/MD.0000000000016509
  • Open


1 Introduction

In the epidemiologic context of the progressive population aging, the early diagnosis of Alzheimer disease (AD) is an emerging problem of growing magnitude. The clinical approach to the cognitive impairment and the AD, which is its most prevalent form,[1,2] has undergone a change in recent years since the definition of NINCD-ADRDA criteria for the clinical diagnosis of AD in 1984.[3] The incorporation of the theory of biomarkers[4] within the classic hypothesis of the amyloid cascade[5] has radically modified the diagnostic approach of AD during the life of the patients, trying to solve the clinical problem of a reliable and early diagnosis of the disease as a continuum.[6]

Nuclear medicine has contributed to the management of dementias and particularly AD, not only by allowing the identification of neurodegeneration before the macroscopic deterioration of the gray matter with positron emission tomography (PET) with F-18-2-fluoro-2-deoxy-D-glucose (FDG), but also by the contribution of amyloid-PET, as a biomarker in vivo with proven analytical validity.[7]

Since its introduction in a research context C-11-PiB[8] has demonstrated to be a useful tool to obtain “in vivo” imaging of the amyloid plaque, one of the hallmarks of AD. It uses, restricted to centers with onsite cyclotron has been overcome with the availability of fluorinated compounds (as F-18-florbetaben [FBB]), which allow a widespread clinical use.[9] Despite progress, amyloid-PET is considered an expensive, complicated and scarcely available procedure, without studies that support it. In general terms, there is not enough evidence to recommend the use in the clinic[10] and some clinical problems remain unresolved, such as the assessment of the validity and reliability of this diagnostic test in clinical practice.[10–14] This situation leads to a vicious circle: its use is not recommended because there is no evidence and there is no evidence because it is not recommended its use.

In the past years the Alzheimer's Association and the Society of Nuclear Medicine and Molecular Imaging convened the Amyloid Imaging Taskforce (AIT), aimed to identify the circumstances under amyloid-PET would have clinical utility, setting its recommendations in the appropriate use criteria (AUC). The AIT considered several situations in which the added certainty of amyloid-PET could be useful to patients and caregivers altering the management of the disease.[11] The AUC from AIT could be considered as restrictive,[11,15] but support the basis for the national consensus.[16] As the authors refers in its report, its suggestions proceed from a literature revision and the interpretation of the previous knowledge in precise clinical settings, but “… empirical evidence of impact on clinical outcomes is not yet available.”[11]

In this scenario, some reports are emerging describing the clinical utility of the amyloid-PET in a clinical naturalistic setting.[17–19] All of them reported relevant changes in the diagnosis, level of diagnostic uncertainty and treatment.

The objective of the present study is located exclusively in patients fulfilling AUC for amyloid-PET and aimed to provide information about the potential benefits of the amyloid-PET in daily clinical management.

2 Methods

2.1 Participants

This case series included patients from 2 level-3 hospitals (A: 1.75 × 106 inhabitants; B: 1.5 × 106 inhabitants) who fulfilled clinical AUC for PET-amyloid scan in agreement with international[11] and national[16] consensuses. According recruitment could be considered as ambispective (in center A in 12 cases and in center B in 6 cases, data were collected retrospectively; in the rest of the cases the information were collected prospectively). The population included in this study corresponds to the total number of patients scanned during the recruitment period between January 2014 and June 2018 without randomization, in a clinical setting: the inclusion in this work does not interfere with the natural clinical workup. This series does not include patients under specific clinical trials.

Four subgroups of these patients were considered for investigation of their beta-amyloid burden to guide clinical management and according to AUC[11,16]:

  • 1. patients with persistent or progressive unexplained mild cognitive impairment (MCI), defined by revised Petersen criteria[20];
  • 2. patients fulfilling core clinical criteria for possible AD but an atypical clinical course with no documented progression in the patient's records;
  • 3. those with progressive cognitive impairment or dementia and atypically early age of onset (≤65 years) and
  • 4. patients fulfilling these core clinical criteria but with cerebrovascular comorbidity, concomitant pharmacologic, neurologic, or cognitive components (mixed etiology).

Exclusion criteria were: the presence of a metabolic disorder (hypothyroidism, vitamin B12, or folic acid deficiencies), psychiatric pathology (schizophrenia or depression), magnetic resonance imaging (MRI) diagnosed cerebrovascular disease (infarction or hemorrhage), neurologic disease affecting gnosis (Parkinsonian syndrome, epilepsy, etc), pregnancy, glycaemia >160 mg/dL, history of substance abuse, or age <18 years. In summary, the selected cases correspond only to patients attended by a cognition trained neurologist, visit at a specific Cognitive Behavioral Neurology Unit, and fulfilling consensual appropriate criteria for amyloid-PET exploration.

All participants gave their written informed consent to participation in the study, which complied with the principles of the Helsinki Declaration and had formal institutional review board approval of each respective Hospital.

2.2 Clinical protocol

All participants were evaluated in a Cognitive Behavioral Neurology Unit (CBNU) by experienced neurologists sharing homogeneous practices in cognitive-behavioral disorders.

2.2.1 Initial assessment

Initial evaluation at CBNU included a medical interview, informant-based history, biochemical panel, and physical and neurological examinations using standardized tests for neuropsychological examination of the domains of orientation, attention, memory, executive function, language, visual and constructive functions, and behavior. Cognition was globally evaluated with the mini-mental estate examination[21] in the Center A and with the FotoTest[22] in the Center B. Brain imaging includes MRI or computed tomography.

In this first visit the potential eligibility was assessed. With the information provided by this first evaluation the neurologist was asked to estimate the probability of AD (vs Non-AD) as responsible of symptomatology. Certainty degree was evaluated using a 5-point Likert scale: 0 (very low probability; 0%–20%); 1 (low probability; 21%–40%); 2 (intermediate probability; 41%–60%); 3 (high probability; 61%–80%); and 4 (practically sure; 81%–100%). At this visit the treatment plan was considered as cognition-specific (eg, acetylcholinesterase inhibitors or memantine hydrochloride); or non-cognition-specific (eg, anxiolytics, hypnotics, antidepressants, antipsychotics, or anticonvulsants).

2.2.2 Specific assessment

If this initial evaluation is inconclusive or insufficient for diagnosis, the patient is transferred to a more specifics procedures, usually in the first line cerebrospinal fluid by spinal puncture biomarkers (CSF-B) and in the second line: amyloid-PET.

When lumbar puncture was not possible (rejected by the patient; not feasible: anticoagulants, spinal problems, and brain or spinal mass) or CSF-B offered nondiagnostic results (technical problems; results near the reference threshold; only 1 or 2 positive result and when result was inconsistent with clinical information),[18] amyloid-PET was performed.

2.2.3 Third (final) diagnosis approach

When amyloid-PET results are available, the neurologist made a re-evaluation of the possible etiological diagnosis (and his confidence level) and about treatment plan, using the same methodology as for prescan evaluation.

In order to assess the incremental diagnostic value of amyloid-PET the outcome variables were diagnostic confidence and treatment plan.

2.3 Amyloid-PET imaging (FBB-PET)

The imaging protocol in both centers complied with international guidelines[9] according supplier recommendations.[23] Extended information is available in Table 1. The FBB was reported blinded to the clinical information by a nuclear medicine physician as positive (loss of grey-white matter contrast; regional cortical tracer uptake at any of the cortical target regions: lateral temporal, frontal, posterior cingulate-precuneus, and parietal), negative (good grey-white matter contrast; no tracer uptake at target regions), or inconclusive for amyloid plaque presence.[23]

Table 1:
Amyloid-PET protocol details.

2.4 Statistical analysis

Mean ± standard deviation values and frequency distributions are reported. We assessed differences in baseline characteristics between groups using analysis of variance, Kruskal–Wallis tests, and Pearson χ2 tests when appropriate. We compare the initial and final diagnostics confidence levels using a paired sample test (Wilcoxon sign rank and McNemar–Bowker tests). We used χ2 tests to assess differences between negative and positive amyloid PET in the treatment plan. We set the level of significance at P < .05. Statistical analyses were performed using SPSS version 15. (IBM, Chicago, IL).

3 Results

3.1 Diagnostic evaluation and treatment before amyloid-pet

A total of 211 patients (115 women and 96 men) with a mean age of 63.54 ± 6.43 years were included. The baseline characteristics of the patients are shown in Table 2. The study of routine dementias, before the amyloid-PET, was completed in 208/211 patients (98.6%), being inconclusive in 201 cases (99.5%). According to the AUC criteria 86 patients (40.7%) had a progressive early-onset dementia (≤65 years); 55 patients (26.1%) shown atypical presentation and/or atypical course; 50 patients (23.7%) suffer persistent or progressive unexplained MCI and in 20 patients (9.5%) a mixed etiology was considered. After this first diagnostic evaluation, the most frequent degree of diagnostic confidence of AD was intermediate probability (category 2) in 108 patients (51.2%); followed by low probability (category 1) in 65 patients (30.8%) and high probability (category 3) in 30 patients (14.2%); in only 4 patients (1.9%) the diagnosis was practically sure (category 4) or very low probability (category 0).

Table 2:
Baseline characteristics of the overall study population and according to the origin center.

Specific treatment for AD was started, before amyloid-PET, in 80 patients (37.9%).

Amyloid-PET was positive in 118 patients (55.9%) and negative in 93 patients (44.1%).

3.2 Diagnostic confidence before and after amyloid pet

After amyloid-PET, the diagnostic confidence showed that the most frequent category was high probability (category 3) in 68 patients (32.2%); followed by the category very low probability (category 0) in 65 patients (30.8%); practically sure (category 4) in 46 patients (21.8%); low probability (category 1) in 28 patients (13.3%); and only 4 patients (1.9%) in intermediate probability (category 2). Consequently, there was a significant increase in categories of greater diagnostic confidence, what is 28.9% in very low probability (category 0), 18% in high probability (category 3) and 19.9% in practically sure (category 4) (P = .05, Wilcoxon test) (Fig. 1).

Figure 1:
Diagnostic confidence before and after amyloid-PET. PET = positron emission tomography.

Analysis of the diagnostic prescan confidence according to amyloid-PET results showed that in both, negative and positive-PET subgroup, the most frequent category was intermediate probability (45.7% and 55.1%, respectively) (Fig. 2). After the amyloid-PET, the diagnostic post-scan confidence showed a very different distribution, that was, in the negative-PET group the most frequent categories are very low probability (70.7%) and low probability (29.3%); while in the positive-PET group were high probability (57.6%) and practically sure (39%) (Fig. 3). Figure 4 shows the change in diagnostic confidence before and after amyloid-PET. Only in 14/211 patients (6.6%) the result of the amyloid-PET did not influence the diagnostic confidence, while in most of the sample, 194 patients (93.4%), the diagnostic confidence improved significantly after amyloid-PET results.

Figure 2:
Diagnostic pre-scan confidence according amyloid-PET results. PET = positron emission tomography.
Figure 3:
Diagnostic confidence in positive and negative amyloid-PET. PET = positron emission tomography.
Figure 4:
Change in diagnostic confidence.

We grouped the categories of greater diagnostic confidence (very low probability and practically sure) and those of less confidence (low, intermediate, and high probability). We found that the diagnostic confidence was not modified for the all cases (8 patients) with a greater prescan diagnostic confidence; however, in 50.7% of cases with less diagnostic confidence prescan, amyloid-PET results conditioned an increase in the degree of confidence diagnostic (P < .001, McNemar test).

3.3 Changes in management

Before amyloid-PET, 80 patients (37.9%) had specific treatment for AD and 131 patients (62.1%) had not initiated treatment. After performing the amyloid-PET, 119 patients (56.4%) had specific AD treatment, while 92 patients (43.6%) had no treatment. That is, 27/80 (33.8%) patients with specific treatment before amyloid-PET stopped receiving it after amyloid-PET study, while in 66/131 (50.4%) patients who did not receive specific treatment before amyloid-PET, started a treatment based on the results of amyloid-PET. Therefore, the therapeutic intention was modified in 93 patients (44.1%). Of these, 66 patients (71%) had a positive amyloid-PET study, while the remaining 27 (29%) had a negative amyloid-PET. In the rest (118 cases; 55.9%) the treatment was not modified, 52/118 (44.1%) with positive amyloid-PET and 66/118 (55.9%) with negative amyloid-PET. A positive result in the amyloid-PET conditioned changes in management in 66/118 patients (55.9%), whereas a negative result in 27/93 (29%) patients (P < .001, χ2 test).

Treatment in the intermediate probability subgroup of the diagnostic confidence prescan was modified in 56/108 patients (51.9%); of these, 42 patients (75%) had a positive amyloid-PET, while in the remaining 14 patients (25%) was negative. In 52/108 patients (48.1%) the management was not modified, 23 patients (44.2%) with positive amyloid-PET and 29 patients (55.8%) negative amyloid-PET.

4 Discussion

In this naturalistic study, we have attempted to estimate the impact of amyloid-PET on the diagnostic certainty and therapeutic approach of AD, added to the routine diagnostic procedures, in a subgroup of patients in which AUC recommend the investigation of their beta-amyloid burden to assess clinical management.[11,16] The population from which patients were recruited is representative of the population of eastern and southern Spain, asking for specialized help in the study of cognitive impairment, when the initial clinical evaluation is insufficient for diagnosis.

The clinical diagnosis suffers from limitations in the actual clinic context.[24] The use of consensual criteria improves this setting, but, even for dementia (not only for MCI), the misdiagnosed rate is high.[25] Final diagnosis is not possible “in vivo” and its approach on basis follow-up of patient could delay the correct treatment. This study arises from this scenario, in which the neurologist cannot wait the clinical evolution, but need to reduce the uncertainty in the diagnosis. Ancillary procedures as CSF-B or amyloid-PET (mandatory for investigation)[4] are now available for clinical use.

Amyloid-PET is a neuroimaging modality that is been increasingly used to assess patients with AD.[11] Several past and present studies investigated the cumulative utility of amyloid imaging on the routine clinical diagnostic assessment of large sets of patients evaluated for cognitive impairment.[19,26–29] This work uses the AUC to select amyloid-PET candidates because there is evidence-based consensus that benefit in decrease diagnostic uncertainty and improve treatment suitability.[18] The AUC could help the neurologist to request an amyloid-PET in an appropriate context, when the evaluation of the dementia supposes a dilemma.[30] This is important because amyloid-PET can also identify amyloid deposition in healthy subjects, who will not necessarily develop the disease as it occurs in a large number of normal elderly[11] or in multiple etiologies such as Lewy bodies or cerebral amyloid angiopathy[4] increasing the false positive rate. On the other hand, the negative predictive value of PET is very important, especially in a disease with high (and growing) prevalence,[17] but always bearing in mind that the rare forms of AD[11] can generate false negatives. In addition, the application of the AUC could help to select amyloid-PET resources rationally justified, due to the low availability of the test or its cost, relevant in health systems.[31]

In the present study, the diagnostic accuracy of amyloid PET was not addressed because does not have final histopathological results. This estimation has been reported in previous works confirmed by final histology[32–34] or supported by clinical follow-up.[7,35] A preliminary and indirect approach of diagnostic accuracy in this series is available in a previous study.[36]

As set above, this work aims to evaluating the clinical usefulness of amyloid-PET as a biomarker of AD, in a naturalistic context. Our results show that amyloid images have an additional value in routine clinical practice. Overall, the amyloid PET study improved the diagnostic confidence in 93.4% patients. Our results are in line with those published by Ceccaldi et al[18] reporting an increase in diagnostic confidence in 81.5% of the subjects after the performance of amyloid-PET. These authors justify this proportion of change as consequence of the high level of pre-test diagnostic uncertainty, which in turn reflects the complexity of the population. At this respect, our population has some peculiarities: is younger, predominantly early onset disease (≤65 years) and lower proportion of atypical forms. In our opinion, although our subpopulations are different, they guarantee the whole spectrum of possibilities found in clinical practice (external validity). In general terms our results are in agreement with others works[17,35,37,38] using a different methodology to estimate diagnostic confidence as the percentage of increase in diagnostic confidence, reporting modifications from 16% to 26% (the modification in 1 step in the 5-point scale used in this work or in Ceccaldi et al,[18] implies a 20%), and in a population not restricted to AUC.[19]

According to the modification of confidence our sample could not be considered as homogeneous. Starting from a clinical setting of inconclusive or insufficient diagnostic, it seems logical to find that after this first evaluation, the categories of diagnostic certainty with the highest proportion of patients are the intermediate categories (specifically in our study, 50% of the patients were classified with an intermediate probability of AD). When the categories are grouped: higher diagnostic confidence (very unlikely and practically sure) and those of less confidence (unlikely, intermediate probably and very probable), we found that the diagnostic confidence was not modified in any cases with a high diagnostic confidence before the scan (8 patients). However, in 50.7% of the cases with less previous diagnostic confidence, PET results conditioned an increase in the degree of diagnostic confidence. These results are closed with those previously published, reporting that the change in diagnosis and the increase in diagnostic confidence were lower in cases with greater pre-PET diagnostic confidence,[7,35,39] therefore, it would support the hypothesis that amyloid PET can have greater impact in situations with significant diagnostic problems, with greater diagnostic uncertainty after a first line protocol for the study of AD has been completed.

Our results show significant changes in diagnostic confidence between positive and negative amyloid-PET subgroups, probably because they represent 2 different scenarios.

On the one hand, in the subgroup of patients with a positive result of amyloid-PET, in respect pre-PET categories there was a relevant migration from intermediate stages to the categories very probable (57.6%) and practically sure (39%). PET with amyloid also showed a clinical utility for cases with more certain diagnosis of AD and a positive result of amyloid-PET was also useful, increasing confidence levels. These results (similar to previously recognized for the CSF-B)[40] support its usefulness available to establish the diagnosis of AD in combination with clinical parameters.

On the other hand in the PET-amyloid negative subgroup, the categories with the highest proportion of patients were very unlikely (70.7%) and unlikely (29.3%). These results are not surprising and come to highlight previous evidence reporting the high negative predictive value of amyloid images in histopathological studies,[33] and indicates that dementia experts generally use a negative amyloid scan as a validated method to exclude a diagnosis of AD in the majority of complex cases; this high negative predictive value is even more valuable when the disease prevalence increases in the general population.

In view of our results, in consonance with other works, amyloid-PET improves diagnostic confidence[18,41] and clinical management.[39,41] Our results support that the use of amyloid-PET should be implemented as a biomarker, not only in a research framework as suggested by the AT (N) system,[42] but also in the study of cognitive impairment in a clinical context.

Regarding changes in the management after amyloid-PET (ie, new medication initiated, medication withdrawn), in our series changing were reported in 44.1% of patients. These results are in agreement with previous studies that used similar criteria, which report changes in treatment from 37% to 68%.[38,43] However, our results are lower than those described by Ceccaldi et al,[18] which reported changes in management for 80.0% of cases; but in this series only are considerate changes in management presuming to have a substantial impact on management (ie, a new drug started, a drug withdrawn, additional diagnostic tests, referred to another specialist), this percentage is reduced to 50.7% of patients, closer to that found in our population. This discrepancy suggests variability in clinical practice: some neurologists indicate a specific treatment before knowing the results of amyloid-PET, while others expect them to indicate the treatment. We believe that this fact reproduces what really happens in the daily clinic. Other diverse factors, such as differences in methodological definitions, selected variables of patient management and diagnostic uncertainty before amyloid-PET, may have contributed to the differences in the findings.

Changes in management were more common in patients with higher diagnostic uncertainty, (the intermediate probability subgroup of AD pre-PET) and the treatment was modified in more than half of the patients (51.9%). This result is not surprisingly and is in the same direction as those previously described by Ceccaldi et al, who report that changes in management were more common in patients with low pre-PET diagnostic confidence.[18]

Interestingly, changes in management were more frequent in patients with positive amyloid-PET compared to negative. In our study a positive result in the amyloid-PET changes therapeutic intention in 55.9% patients, whereas a negative result in 29%. These results are inconsistent with those previously published by other series, in which the treatment changes were similar in patients with positive or negative PET amyloid.[18] As set above, these discrepancies support the variability in clinical practice regarding the time to start specific treatment of AD respect to amyloid-PET report.

This study is not specifically a cost-analysis and our contribution cannot be more than speculative but could not be indifferent to this aspect. The prognostic and preventive implications of an early and clear diagnosis of AD have direct repercussions in the health systems,[44] patients[6,19] and caregivers.[27] Cannot ignore the intangible costs and the fact that an early diagnosis allows to make decisions that the illness must face. New therapies are addressed to stop the progression of disease and it is desirable to be effective in early stages of process.[45] Evidently, the implementation of specific early therapies could be more cost-effective than the costs generated by the delay in the application of a treatment, when only secondary or tertiary prevention can be done.[6]

This study has some limitations. First, in our work postmortem verification was not available and the main outcome measure was the change in diagnostic confidence, and this outcome reflects the beliefs of clinicians. However, the proportional change observed in diagnostic confidence is in agreement with others previous studies[18,27,35,37] with a similar methodological approach. Could be desirable that a long clinical follow-up of the population provides information on the relation of amyloid-PET results with the parameters of diagnosis certainty and treatment optimization. Second, the cases were recruited in a clinical frame setting, without randomization, which may have led to an overestimation or underestimation of the effect of amyloid-PET in diagnostic confidence, but this naturalistic study provides evidence that the interpretation of amyloid-PET is associated with a significant improvement in diagnostic confidence, and it is worthy of clinical promotion and application. Third, most patients were included in a tertiary referral center, with a high proportion of early-onset and atypical clinical presentations. This can hinder translation to primary and secondary-care levels, where the populations tend to be older, more advanced or less complex. However, in our opinion amyloid-PET should only be performed after exhaustive standardized protocols applied by trained staff.[11] Finally, amyloid-PET scans have been reported only by visual analysis, grounded in the subjective criteria of qualified specialists. Semiquantitative procedures could be of interest in inconclusive studies (none in our series) and provide complementary objective information. In the project phase of this work, the investigation team decides does not modify the standardized protocol used in daily practice based only in visual analysis to maximize the external validity of our results to any other center.

5 Conclusions

In conclusion, this naturalistic study provides evidence that the performance of amyloid-PET is associated with a significant improvement in diagnostic confidence and has a high impact on the therapeutic management of patients with MCI, fulfilling clinical AUC, who usually present uncertain clinical features as early-onsets, atypical, mixed and rapid progressing presentations. Consequently we strongly recommend, based on existing evidence and our results, to implement amyloid PET in AUC in daily clinical practice.

Author contributions

Conceptualization: Eva María Triviño-Ibáñez, Raquel Sánchez-Vañó, Pablo Sopena-Novales, Juan Carlos Romero-Fábrega, Cristóbal Carnero Pardo, María Dolores Martínez Lozano, Manuel Gómez-Río.

Data curation: Eva María Triviño-Ibáñez, Raquel Sánchez-Vañó, Pablo Sopena-Novales, Juan Carlos Romero-Fábrega, Antonio Rodríguez-Fernández, Cristóbal Carnero Pardo, María Dolores Martínez Lozano, Manuel Gómez-Río.

Formal analysis: Eva María Triviño-Ibáñez, Raquel Sánchez-Vañó, Pablo Sopena-Novales, Cristóbal Carnero Pardo, Manuel Gómez-Río.

Funding acquisition: Eva María Triviño-Ibáñez, Raquel Sánchez-Vañó, Pablo Sopena-Novales, Cristóbal Carnero Pardo, María Dolores Martínez Lozano, Manuel Gómez-Río.

Investigation: Eva María Triviño-Ibáñez, Raquel Sánchez-Vañó, Pablo Sopena-Novales, Juan Carlos Romero-Fábrega, Cristóbal Carnero Pardo, María Dolores Martínez Lozano, Manuel Gómez-Río.

Methodology: Eva María Triviño-Ibáñez, Raquel Sánchez-Vañó, Pablo Sopena-Novales, Juan Carlos Romero-Fábrega, Antonio Rodríguez-Fernández, Cristóbal Carnero Pardo, María Dolores Martínez Lozano, Manuel Gómez-Río.

Project administration: Eva María Triviño-Ibáñez, Raquel Sánchez-Vañó, Pablo Sopena-Novales, Juan Carlos Romero-Fábrega, Cristóbal Carnero Pardo, Manuel Gómez-Río.

Resources: Eva María Triviño-Ibáñez, Raquel Sánchez-Vañó, Pablo Sopena-Novales, Juan Carlos Romero-Fábrega, Cristóbal Carnero Pardo, Manuel Gómez-Río.

Software: Raquel Sánchez-Vañó, Pablo Sopena-Novales, Cristóbal Carnero Pardo, Manuel Gómez-Río.

Supervision: Eva María Triviño-Ibáñez, Raquel Sánchez-Vañó, Pablo Sopena-Novales, Cristóbal Carnero Pardo, María Dolores Martínez Lozano, Manuel Gómez-Río.

Validation: Eva María Triviño-Ibáñez, Raquel Sánchez-Vañó, Pablo Sopena-Novales, Antonio Rodríguez-Fernández, Cristóbal Carnero Pardo, Manuel Gómez-Río.

Visualization: Eva María Triviño-Ibáñez, Raquel Sánchez-Vañó, Pablo Sopena-Novales, Cristóbal Carnero Pardo, Manuel Gómez-Río.

Writing – original draft: Eva María Triviño-Ibáñez, Raquel Sánchez-Vañó, Manuel Gómez-Río.

Writing – review and editing: Eva María Triviño-Ibáñez, Raquel Sánchez-Vañó, Manuel Gómez-Río.

Eva M Triviño-Ibáñez orcid: 0000-0001-6604-6608.


[1]. 2018 Alzheimer's disease facts and figures. Alzheimer's Dement 2018;14:367–429.
[2]. Niu H, Álvarez-Álvarez I, Guillén-Grima F, et al. Prevalence and incidence of Alzheimer's disease in Europe: a meta-analysis. Neurologia 2017;32:523–32.
[3]. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939–44.
[4]. Jack CR, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010;9:119–28.
[5]. Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med 2016;8:595–608.
[6]. Dubois B, Hampel H, Feldman HH, et al. Preclinical Alzheimer's disease: definition, natural history, and diagnostic criteria. Alzheimers Dement 2016;12:292–323.
[7]. Teipel S, Drzezga A, Grothe MJ, et al. Multimodal imaging in Alzheimer's disease: validity and usefulness for early detection. Lancet Neurol 2015;14:1037–53.
[8]. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004;55:306–19.
[9]. Minoshima S, Drzezga AE, Barthel H, et al. SNMMI procedure standard/EANM practice guideline for amyloid PET imaging of the brain 1.0. J Nucl Med 2016;57:1316–22.
[10]. Morbelli S, Bauckneht M, Scheltens P. Imaging biomarkers in Alzheimer's disease: added value in the clinical setting. Q J Nucl Med Mol Imaging 2017;61:360–71.
[11]. Johnson KA, Minoshima S, Bohnen NI, et al. Appropriate use criteria for amyloid PET: a report of the amyloid imaging task force, the society of nuclear medicine and molecular imaging, and the Alzheimer's association. J Nucl Med 2013;54:476–1490.
[12]. Martínez G, Vernooij RW, Fuentes Padilla P, et al. 18F PET with florbetaben for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev 2017;11:CD012883.
[13]. Martínez G, Vernooij RW, Fuentes Padilla P, et al. 18F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev 2017;11:CD012884.
[14]. Martínez G, Vernooij RW, Fuentes Padilla P, et al. 18F PET with florbetapir for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev 2017;11:CD012216.
[15]. Booij J, Arbizu J, Darcourt J, et al. Appropriate use criteria for amyloid PET imaging cannot replace guidelines: on behalf of the European Association of Nuclear Medicine. Eur J Nucl Med Mol Imaging 2013;40:1122–5.
[16]. Arbizu J, García-Ribas G, Carrió I, et al. Recommendations for the use of PET imaging biomarkers in the diagnosis of neurodegenerative conditions associated with dementia: consensus proposal from the SEMNIM and SEN. Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) 2015;34:303–13.
[17]. Boccardi M, Altomare D, Ferrari C, et al. Assessment of the incremental diagnostic value of florbetapir F 18 imaging in patients with cognitive impairment: the incremental diagnostic value of amyloid PET with [18F]-florbetapir (INDIA-FBP) study. JAMA Neurol 2016;73:1417–24.
[18]. Ceccaldi M, Jonveaux T, Verger A, et al. Added value of 18F-florbetaben amyloid PET in the diagnostic workup of most complex patients with dementia in France: a naturalistic study. Alzheimers Dement 2018;14:293–305.
[19]. de Wilde A, van Maurik IS, Kunneman M, et al. Alzheimer's biomarkers in daily practice (ABIDE) project: rationale and design. Alzheimers Dement (Amst) 2017;6:143–51.
[20]. Winblad B, Palmer K, Kivipelto M, et al. Mild cognitive impairment–beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 2004;256:240–6.
[21]. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–98.
[22]. Carnero Pardo C, Sáez-Zea C, Montiel Navarro L, et al. Diagnostic accuracy of the Phototest for cognitive impairment and dementia. Neurologia 2007;22:860–9.
[23]. Sabri O, Seibyl J, Rowe C, et al. Beta-amyloid imaging with florbetaben. Clin Transl Imaging 2015;3:13–26.
[24]. Beach TG, Monsell SE, Phillips LE, et al. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010. J Neuropathol Exp Neurol 2012;71:266–73.
[25]. Sommerlad A, Perera G, Singh-Manoux A, et al. Accuracy of general hospital dementia diagnoses in England: sensitivity, specificity, and predictors of diagnostic accuracy 2008–2016. Alzheimers Dement 2018;14:933–43.
[26]. Degerman Gunnarsson M, Lindau M, Santillo AF, et al. Re-evaluation of clinical dementia diagnoses with pittsburgh compound B positron emission tomography. Dement Geriatr Cogn Dis Extra 2013;3:472–81.
[27]. Bensaïdane MR, Beauregard J-M, Poulin S, et al. Clinical utility of amyloid PET imaging in the differential diagnosis of atypical dementias and its impact on caregivers. J Alzheimers Dis 2016;52:1251–62.
[28]. Schönecker S, Prix C, Raiser T, et al. Amyloid positron-emission-tomography with [18 F]-florbetaben in the diagnostic workup of dementia patients. Nervenarzt 2017;88:156–61.
[29]. Boccardi M, Festari C, Altomare D, et al. Assessing FDG-PET diagnostic accuracy studies to develop recommendations for clinical use in dementia. Eur J Nucl Med Mol Imaging 2018;45:1470–86.
[30]. Apostolova LG, Haider JM, Goukasian N, et al. Critical review of the appropriate use criteria for amyloid imaging: effect on diagnosis and patient care. Alzheimers Dement (Amst) 2016;5:15–22.
[31]. Lundeen TF, Seibyl JP, Covington MF, et al. Signs and artifacts in amyloid PET. Radiographics 2018;38:2123–33.
[32]. Clark CM, Pontecorvo MJ, Beach TG, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-plaques: a prospective cohort study. Lancet Neurol 2012;11:669–78.
[33]. Sabri O, Sabbagh MN, Seibyl J, et al. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study. Alzheimers Dement 2015;11:964–74.
[34]. Curtis C, Gamez JE, Singh U, et al. Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density. JAMA Neurol 2015;72:287–94.
[35]. Ossenkoppele R, Prins ND, Pijnenburg YAL, et al. Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimers Dement 2013;9:414–21.
[36]. Segovia F, Gómez-Río M, Sánchez-Vañó R, et al. Usefulness of dual-point amyloid PET scans in appropriate use criteria: a multicenter study. J Alzheimers Dis 2018;65:765–79.
[37]. Weidman DA, Zamrini E, Sabbagh MN, et al. Added value and limitations of amyloid-PET imaging: review and analysis of selected cases of mild cognitive impairment and dementia. Neurocase 2017;23:41–51.
[38]. Zwan MD, Bouwman FH, Konijnenberg E, et al. Diagnostic impact of [18F]flutemetamol PET in early-onset dementia. Alzheimers Res Ther 2017;9:2.
[39]. Grundman M, Pontecorvo MJ, Salloway SP, et al. Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline. Alzheimer Dis Assoc Disord 2013;27:4–15.
[40]. Gooblar J, Carpenter BD, Coats MA, et al. The influence of cerebrospinal fluid (CSF) biomarkers on clinical dementia evaluations. Alzheimers Dement 2015;11:533–40.e2.
[41]. Pontecorvo MJ, Siderowf A, Dubois B, et al. Effectiveness of florbetapir PET imaging in changing patient management. Dement Geriatr Cogn Disord 2017;44:129–43.
[42]. Jack CR, Bennett DA, Blennow K, et al. NIA-AA research framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement 2018;14:535–62.
[43]. Pontecorvo MJ, Siderowf A, Grundman M, et al. A randomized, controlled, multicenter, international study of the impact of florbetapir (18F) PET amyloid imaging on patient management and outcome. Alzheimer's Dementia 2015;11(7 Supplement):334.
[44]. Jia J, Wei C, Chen S, et al. The cost of Alzheimer's disease in China and re-estimation of costs worldwide. Alzheimers Dement 2018;14:483–91.
[45]. Khachaturian AS, Hayden KM, Mielke MM, et al. Future prospects and challenges for Alzheimer's disease drug development in the era of the NIA-AA research framework. Alzheimers Dement 2018;14:532–4.

Alzheimer's disease; amyloid PET; appropriate use criteria; florbetaben PET; mild cognitive impairment

Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc.